2011 - 10th Meeting - IHCTAS


Concurrent Sessions from Abstracts. Session 1

5.1 - Validating the Banff Classification of Rejection in Vascularized Composite Allografts and a Look Beneath the Surface

Presenter: Jinny, Ha, Baltimore, MD, USA
Authors: Jinny Ha, Cinthia Drachenberg, Gerhard Mundinger, John Papadimitriou, Borisiav Alexiev, Abdolreza Haririan, Luke Jones, Stephen Bartlett, Eduardo Rodriguez, Rolf Barth.


Validating the Banff Classification of Rejection in Vascularized Composite Allografts and a Look Beneath the Surface

Jinny Ha1, Cinthia Drachenberg2, Gerhard Mundinger3, John Papadimitriou2, Borisiav Alexiev2, Abdolreza Haririan4, Luke Jones1, Stephen Bartlett1, Eduardo Rodriguez3, Rolf Barth5.

1Department of Surgery, University of Maryland School of Medicine; 2Department of Pathology, University of Maryland School of Medicine; 3Division of Plastics, Reconstructive, and Maxillofacial Surgery, University of Maryland School of Medicine; 4Division of Nephrology, University of Maryland School of Medicine; 5Division of Transplant Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.

The successes of the limited number of hand and face transplants have made vascularized composite allografts (VCA) a clinical reality; however, pathologists have limited comparative experience in utilizing the Banff criteria for rejection. Therefore, we have assessed the clinical utility and reproducibility of the Banff schema for the skin component of VCA in our non-human primate models.

VCA biopsies from 28 Cynomolgus macaque recipients of a fibula to radius or heterotopic facial subunit VCA were included for analysis. A total of 198 H&E-stained biopsies were reviewed by 3 pathologists. The Banff CTA 2007 grading schema was used to score the severity of rejection. Deeper structures were evaluated when available. Kappa (k) statistical analysis was used to determine inter-rater agreement.

There was substantial inter-rater agreement with k=0.66 (p<0.0001). Highest concordance was seen when identifying grade IV rejection (k=0.75). There was moderate agreement for grades 0 to III (k=0.53-0.60). Perivascular and soft tissue infiltrates were seen in 70% of the specimens examined. These findings were seen in normal skin and in all grades of rejection. Deep structures were observed in 162 specimens. Notable changes in deep tissue vessels were observed in biopsies with grade III/IV rejection. Intimal arteritis was seen in 50% and 42.1% of the samples with grade III and IV rejection, respectively. Arterial necrosis (31.6%) and thrombosis (36.8%) were seen in biopsies with grade IV rejection.

The Banff schema for acute rejection is reproducible and reliable in monitoring graft rejection in our VCA model. Perivascular and soft tissue infiltrates appear to be a non-specific finding, seen in the absence and presence of rejection. Intimal arteritis, arterial necrosis, and thrombosis are associated with advanced rejection. There may be additional diagnostic and prognostic markers of rejection within the deep tissues, which the current Banff schema for VCA does not address.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi